Table 1.
Demographic and Clinical Characteristics of Patients Receiving Escitalopram and Placebo
| Baseline Characteristics | Escitalopram (n=21) | Placebo (n=20) | Summary statistic | p-value |
|---|---|---|---|---|
| Age, mean (SD), year | 14.9±1.7 | 15.0±1.6 | −0.18 | 0.86 |
| Female, n (%) | 16 (76) | 14 (70) | 0.20 | 0.66 |
| Full scale IQ, mean (SD) | 106±10 | 104±11 | 0.48 | 0.64 |
| Race | 1.51 | 0.87 | ||
| Asian | 0 (17) | 1 (6) | ||
| Black and African American | 1 (0) | 1 (6) | ||
| Caucasian | 19 (83) | 17 (81) | ||
| Other | 1 (0) | 1 (6) | ||
| Hispanic or Latino | 2 (0) | 0 (0) | 0.49 | |
|
| ||||
| PARS score, baseline | 17±2 | 17±3 | 0.17 | 0.86 |
| PARS score, week 8/ET | 7±6 | 15±3 | −2.37 | 0.02 |
| CGI-Severity score, median | 4 | 4 | 0.22 | |
|
| ||||
| Secondary diagnoses | ||||
| Separation anxiety disorder | 3 (14) | 4 (20) | 0.70 | |
| Panic disorder | 10 (48) | 12 (60) | 0.54 | |
| Agoraphobia | 6 (29) | 6 (30) | 1.00 | |
| ADHD | 4 (19) | 4 (20) | 1.00 | |
| Specific phobia | 7 (33) | 2 (10) | 0.13 | |
|
| ||||
| Prior SSRI/SNRI treatment, n (%) | 5 (24) | 6 (19) | 0.20 | 0.73 |
CGI-S, Clinical Global Impression Scale-Severity; CDRS-R, Children’s Depression Rating Scale-Revised; PARS, Pediatric Anxiety Rating Scale; ADHD, Attention/Deficit-Hyperactivity Disorder; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor.